Utilization of the multiple sclerosis functional composite in follow-up: Relationship to disease phenotype, disability and treatment strategies

Journal of the Neurological Sciences

Volumn 232, Issue 1-2, 2005, Pages 65-69

  Ozakbas, Serkan ^a   Ormeci, Burcu ^a   Idiman, Egemen ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Expanded disability status scale; Follow up; Immunomodulation; Multiple sclerosis; Multiple sclerosis functional composite; Remission

Indexed keywords

GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; PATIENT; PHENOTYPE; PRIORITY JOURNAL; RATING SCALE; RELAPSE; SCORING SYSTEM; SENSITIVITY ANALYSIS; TIME; VALIDATION PROCESS;

EID: 17844404779     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2005.01.008     Document Type: Article

References (15)

1. J.F. Kurtzke Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
2. R. Rudick, J. Antel, and C. Confavreux Clinical outcomes assessment in multiple sclerosis Ann Neurol 40 1996 467 479
3. R. Rudick, J. Antel, and C. Confavreux Recommendations from the national multiple sclerosis society clinical outcomes assessment task force Ann Neurol 42 1997 379 382
4. G.R. Cutter, M.L. Baier, and R.A. Rudick Development of a multiple sclerosis functional composite as a clinical trial outcome measure Brain 122 1999 871 882
5. J.S. Fischer for the National MS Society Clinical Outcomes Assessment Task Force The multiple sclerosis functional composite measure: an integrated approach to MS clinical outcome assessment Mult Scler 5 1999 244 250
6. S. Ozakbas, I. Cagiran, B. Ormeci, and E. Idiman Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis J Neurol Sci 208 2004 3 7
7. R.A. Rudick, G. Cutter, M. Baier, E. Fisher, D. Dougherty, and B. Weinstock-Guttman Use of multiple sclerosis functional composite to predict disability in relapsing MS Neurology 56 2001 1324 1330
8. W.I. McDonald, A. Compston, G. Edan, D. Goodkin, H.P. Hartung, and F.D. Lublin Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis Ann Neurol 50 2001 121 127
9. E.W. Willoughby, and D.W. Paty Scales for rating impairment in multiple sclerosis: a critique Neurology 38 1988 1793 1798
10. J.S. Fischer for the National MS Society Clinical Outcomes Assessment Task Force The multiple sclerosis functional composite measure: an integrated approach to MS clinical outcome assessment Mult Scler 5 1999 244 250
11. J.S. Fischer, A.J. Jak, J.E. Knicker, and R.A. Rudick Administration and scoring manual for the multiple sclerosis functional composite measure (MSFC) 1999 National Multiple Sclerosis Society New York (NY)
12. J.A. Cohen, J.S. Fischer, B.A. Bolibrush, A.J. Jak, J.E. Kniker, and L.A. Mertz İntrarate and interrater reliability of the MS functional composite outcome measure Neurology 54 2000 802 806
13. N.F. Kalkers, V. De Groot, R.H. Lazeron, J. Killestein, H.J. Ader, and F. Barkhof MS functional composite. Relation to disease phenotype and disability strata Neurology 54 2000 1233 1239
14. B.G. Vickrey, R.D. Hays, R. Harooni, L.W. Myers, and G.W. Ellison A health-related quality of life measure for multiple sclerosis Qual Life Res 4 1995 187 206
15. J.A. Cohen, G.R. Cutter, J.S. Fischer, A.D. Goodman, F.R. Heidenreich, and A.J. Jak Use of multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial Arch Neurol 58 2001 961 967